ES2184293T3 - Composiciones farmaceuticas administrables por via oral que comprenden una benzhidrilpiperazina y una ciclodextrina. - Google Patents

Composiciones farmaceuticas administrables por via oral que comprenden una benzhidrilpiperazina y una ciclodextrina.

Info

Publication number
ES2184293T3
ES2184293T3 ES98931849T ES98931849T ES2184293T3 ES 2184293 T3 ES2184293 T3 ES 2184293T3 ES 98931849 T ES98931849 T ES 98931849T ES 98931849 T ES98931849 T ES 98931849T ES 2184293 T3 ES2184293 T3 ES 2184293T3
Authority
ES
Spain
Prior art keywords
pharmaceutical compositions
benzhydr
cyclodextrine
piperazine
oral route
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98931849T
Other languages
English (en)
Other versions
ES2184293T5 (es
Inventor
Domenico Fanara
Monique Berwaer
Philippe Nolf
Henri Vranckx
Michel Deleers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3890611&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2184293(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB SA filed Critical UCB SA
Publication of ES2184293T3 publication Critical patent/ES2184293T3/es
Application granted granted Critical
Publication of ES2184293T5 publication Critical patent/ES2184293T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a composiciones farmacéuticas para administración oral, que comprenden una sustancia activa que pertenece a la familia de las benzohidrilpiperazinas sustituidas y al menos una ciclodextrina.
ES98931849T 1997-07-03 1998-07-02 Composiciones farmaceuticas administrables por via oral, que comprenden una benzhidrilpiperazina y una ciclodextrina. Expired - Lifetime ES2184293T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE9700572 1997-07-03
BE9700572A BE1011251A3 (fr) 1997-07-03 1997-07-03 Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.

Publications (2)

Publication Number Publication Date
ES2184293T3 true ES2184293T3 (es) 2003-04-01
ES2184293T5 ES2184293T5 (es) 2006-01-16

Family

ID=3890611

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98931849T Expired - Lifetime ES2184293T5 (es) 1997-07-03 1998-07-02 Composiciones farmaceuticas administrables por via oral, que comprenden una benzhidrilpiperazina y una ciclodextrina.

Country Status (21)

Country Link
US (1) US6455533B1 (es)
EP (1) EP0994710B2 (es)
JP (2) JP2002508773A (es)
KR (1) KR100551510B1 (es)
CN (1) CN1150900C (es)
AT (1) ATE224717T1 (es)
AU (1) AU727140B2 (es)
BE (1) BE1011251A3 (es)
BR (1) BR9810495A (es)
CA (1) CA2294783C (es)
DE (1) DE69808297T3 (es)
DK (1) DK0994710T4 (es)
ES (1) ES2184293T5 (es)
HK (1) HK1029060A1 (es)
ID (1) ID23806A (es)
IL (1) IL133397A (es)
NZ (1) NZ501820A (es)
PL (1) PL192348B1 (es)
PT (1) PT994710E (es)
RU (1) RU2192863C2 (es)
WO (1) WO1999001133A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0028575D0 (en) * 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins
CZ20032138A3 (cs) * 2001-02-05 2005-03-16 R. P. Scherer Technologies, Inc. Způsoby a prostředky pro zeslabení chuti farmaceuticky aktivních činidel
CN101632642B (zh) * 2002-01-15 2011-06-08 Ucb法奇姆股份有限公司 口感和稳定性改善的配方
RU2004129573A (ru) * 2002-04-04 2005-04-10 Пфайзер Продактс Инк. (Us) Жевательная таблетка с приятным вкусом
BRPI0513455A (pt) * 2004-07-22 2008-05-06 Pfizer Prod Inc formulação para mascaramento de sabor compreendendo o fármaco em uma forma de dissolução retardada e/ou ciclodextrina em uma forma de dissolução melhorada
US20060147518A1 (en) * 2004-12-30 2006-07-06 Pierre Fabre Medicament Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it
US20060198885A1 (en) * 2005-02-22 2006-09-07 Sun Pharmaceutical Industries Ltd. Oral pharmaceutical composition
US20070086974A1 (en) * 2005-10-06 2007-04-19 Gawande Rahul S Cetirizine compositions
WO2007144902A1 (en) * 2006-06-12 2007-12-21 Jubliant Organosys Limited Chewable bilayer tablet formulation
JP2008143807A (ja) * 2006-12-07 2008-06-26 Sato Pharmaceutical Co Ltd 感冒薬カプセル剤及びその製造方法
DK2178521T3 (da) * 2007-07-11 2014-04-28 Fertin Pharma As Stabilt medicinsk tyggegummi omfattende cyclodextrin-inklusionskompleks
EP2550967A1 (en) * 2007-07-11 2013-01-30 Fertin Pharma A/S Compressed chewing gum tablet comprising taste-masking agent
JPWO2009054432A1 (ja) * 2007-10-26 2011-03-03 第一三共株式会社 口腔内速崩壊性医薬組成物およびその製造方法
US8138192B2 (en) * 2007-10-31 2012-03-20 Genebiology, Inc. Injectable meclizine formulations and methods
EP2067469A1 (en) 2007-11-06 2009-06-10 Teva Pharmaceutical Industries Ltd. Chewable formulations
ES2564056T3 (es) * 2008-09-05 2016-03-17 Johnson & Johnson Consumer Inc. Método para hacer pastillas de cetirizina
WO2011110939A2 (en) 2010-03-11 2011-09-15 Rubicon Research Private Limited Pharmaceutical compositions of substituted benzhydrylpiperazines
HK1161509A2 (en) * 2010-06-04 2012-07-27 Comprehensive Drug Entpr Ltd Oral meclizine aqueous formulations with taste flavoring agent
CN101905027A (zh) * 2010-07-27 2010-12-08 北京华禧联合科技发展有限公司 含米格列奈钙和环糊精的口服药用组合物
SG188509A1 (en) 2010-09-13 2013-04-30 Bev Rx Inc Aqueous drug delivery system comprising off - flavor masking agent
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
RU2589833C2 (ru) * 2013-12-12 2016-07-10 Общество С Ограниченной Ответственностью "Фарма Старт" Твердая лекарственная форма препарата седативного и снотворного действия
US20170105988A1 (en) * 2014-03-27 2017-04-20 Ucb Biopharma Sprl Pharmaceutical Compositions Comprising Levocetirizine
PL3524595T3 (pl) 2014-08-28 2022-10-31 Eisai R&D Management Co., Ltd. Pochodna chinoliny o wysokiej czystości i sposób jej wytwarzania
SI3263106T1 (sl) 2015-02-25 2024-02-29 Eisai R&D Management Co., Ltd. Postopek zatiranja grenkobe derivata kinolina
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
MX2017015896A (es) 2015-06-16 2018-08-09 Eisai R&D Man Co Ltd Agente anticancerigeno.
KR102110304B1 (ko) * 2017-06-30 2020-05-14 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성 및 복약순응도가 향상된 복합 츄어블정 및 그 제조방법
EP4247331A1 (en) 2020-11-18 2023-09-27 BioPharma Synergies, S. L. Orodispersible powder composition comprising an antihistamine compound

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK154078C (da) * 1981-02-06 1989-05-22 Ucb Sa Analogifremgangsmaade til fremstilling af 2-(2-(4-(diphenyl-methyl)-1-piperazinyl)ethoxy)-acetamider eller syreadditionssalte heraf
JPS60204712A (ja) * 1984-03-29 1985-10-16 Ss Pharmaceut Co Ltd 塩酸メクリジンの安定化液状組成物
JPS63243031A (ja) † 1987-03-28 1988-10-07 Tokyo Tanabe Co Ltd 胆汁酸の固形製剤
US5206025A (en) * 1989-05-24 1993-04-27 Rhone-Poulenc Sante Porous pharmaceutical form and its preparation
FR2647343B1 (fr) 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
ATE170749T1 (de) † 1992-09-24 1998-09-15 Sepracor Inc Verwendung von (-) cetirizin zur behandlung allergischer rhinitis und und asthma
TW401300B (en) * 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
US5866179A (en) 1996-05-03 1999-02-02 Avant-Garde Technologies & Products S.A. Medicated chewing gum and a process for preparation thereof
GB0028575D0 (en) * 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins
BRPI0513455A (pt) * 2004-07-22 2008-05-06 Pfizer Prod Inc formulação para mascaramento de sabor compreendendo o fármaco em uma forma de dissolução retardada e/ou ciclodextrina em uma forma de dissolução melhorada

Also Published As

Publication number Publication date
CN1261799A (zh) 2000-08-02
CN1150900C (zh) 2004-05-26
DE69808297T3 (de) 2006-01-19
BR9810495A (pt) 2000-09-12
WO1999001133A1 (fr) 1999-01-14
CA2294783A1 (fr) 1999-01-14
ID23806A (id) 2000-05-11
US6455533B1 (en) 2002-09-24
IL133397A (en) 2005-07-25
DE69808297D1 (de) 2002-10-31
BE1011251A3 (fr) 1999-06-01
EP0994710B2 (fr) 2005-09-21
ATE224717T1 (de) 2002-10-15
EP0994710A1 (fr) 2000-04-26
NZ501820A (en) 2000-10-27
EP0994710B1 (fr) 2002-09-25
IL133397A0 (en) 2001-04-30
PT994710E (pt) 2003-02-28
JP2007091760A (ja) 2007-04-12
DE69808297T2 (de) 2003-04-17
RU2192863C2 (ru) 2002-11-20
KR20010014398A (ko) 2001-02-26
HK1029060A1 (en) 2001-03-23
CA2294783C (fr) 2006-11-14
KR100551510B1 (ko) 2006-02-13
PL192348B1 (pl) 2006-10-31
US20020032217A1 (en) 2002-03-14
AU727140B2 (en) 2000-12-07
DK0994710T4 (da) 2005-10-17
AU8201598A (en) 1999-01-25
DK0994710T3 (da) 2003-01-20
ES2184293T5 (es) 2006-01-16
PL337794A1 (en) 2000-09-11
JP2002508773A (ja) 2002-03-19

Similar Documents

Publication Publication Date Title
ES2184293T3 (es) Composiciones farmaceuticas administrables por via oral que comprenden una benzhidrilpiperazina y una ciclodextrina.
CO4940450A1 (es) Formulaciones farmaceuticas que contienen voriconazol
BR9611802A (pt) Composições farmacêuticas
BR0015188A (pt) Composições farmacêuticas
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
HN1999000066A (es) Formulaciones farmaceuticas
ES2181055T3 (es) Formulaciones galenicas que contienen antagonistas de opiaceos.
DK1037607T3 (da) Hidtil ukendt suppositoriumsform, der omfatter en syrelabil aktiv forbindelse
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
GT199800101A (es) Composicion farmaceutica solida que contiene un derivado de benzofurano.
CO5590918A2 (es) Formulaciones
HK1034183A1 (en) Galenic formulations of meloxicam for oral administration.
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
ATE303149T1 (de) Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
FR2764889B1 (fr) Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
DK1104289T3 (da) Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister
DK0930077T3 (da) Cyclodextrinpræparater indeholdende et avermectin- eller milbemycinderivat
ATE353224T1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
ES2191241T3 (es) Preparaciones farmaceuticas por via oral que comprenden s-(3-hidroxipropil)-l-cisteina.
MA26788A1 (fr) COMPOSITIONS PHARMACEUTIQUES DESTINÉES à L'ADMINISTRATION PAR VOIE ORALE DE PHLOROGLUCINOL ET LEUR PRÉPARATION
DE60214476D1 (de) Pharmazeutische Zubereitungen, Wirkstoffe enthaltend, die sich für unerlaubte Verabreichung anbieten
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
SE9403137D0 (sv) Derivatives of carbohydrates and compositions containing them
BR0011845A (pt) Complexo farmacêutico
DK1011329T3 (da) 7-Methylthiooxomethyl- og 7-methylthiodioxomethyl-paclitaxeler